FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [LPTX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>ONSI DOUGLAS E</u>				<i>7</i> L // 11	TITLE	711	LOTICE	<u>J, 1</u>	<u>. 10.</u> [I	A I A J		X Director	•		10% Ow	ner	
(Last)	(F	irst)	(Middle)		Date of Earliest Transaction (Month/Day/Year)						_	X Officer below)	(give title		Other (spelow)	pecify	
C/O LEAP THERAPEUTICS, INC.				0	09/01/2022						CEO,CFO,Pres.,GC,Treas.,&Sec.						
47 THORNDIKE STREET SUITE B1-1																	
				4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)												Line	,		D = = = =#:	D	
CAMBR	IDGE M	ÍΑ	02141										-	ed by One led by More		J	ng
-													Person		tilali C	ле кероп	ng
(City)	(S	State)	(Zip)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,			Code (Instr.				Beneficia Owned F	Form (D) or ollowing (I) (In		Direct Indirect E r. 4) C	7. Nature of Indirect Beneficial Ownership	
								Code	٧	Amount	(A) c (D)	Price	Reported Transacti (Instr. 3 a	Reported Transaction(s) (Instr. 3 and 4)			nstr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
(e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code	5. Number of Derivative Securities Acquired (A or f (D) (Instr. 3, 4 and 5)		e s i (A) sed str.	Expiration Date (Month/Day/Year)			7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	ly [10. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	(5)		
Employee Stock Option (Right to Buy)	\$1.43	09/01/2022		A		200,000		(1)	08	8/31/2032	Common Stock	200,000	\$0	200,000	0	D	

Explanation of Responses:

1. The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date.

/s/ Douglas E. Onsi

09/02/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).